CervoMed Publishes Corporate Presentation on Neflamapimod Development for Age-Related Brain Disorders

Reuters

Feb 18

<a href="https://laohu8.com/S/CRVO">CervoMed</a> Publishes Corporate Presentation on Neflamapimod Development for Age-Related Brain Disorders

CervoMed Inc. highlighted progress for its lead candidate neflamapimod, an oral small-molecule p38α inhibitor being developed for age-related brain disorders. The company outlined plans to initiate a Phase 3 trial in dementia with Lewy bodies in the second half of 2026, and said Phase 2a enrollment is ongoing in non-fluent variant primary progressive aphasia and recovery after ischemic stroke, with data readouts expected in mid-2026 (nfvPPA) and the second half of 2026 (RAS). The presentation also summarized prior DLB study findings, including Phase 2a results showing improvements on CDR-SB and gait measures, and Phase 2b extension-phase analyses in which participants receiving a drug product batch that achieved target plasma concentrations showed improved CDR-SB and ADCS-CGIC outcomes versus an earlier batch. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief on February 18, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2612444486"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612444486\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612444486?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-18 23:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612444486","market":"fut","top_or_hot":-1,"title":"CervoMed Publishes Corporate Presentation on Neflamapimod Development for Age-Related Brain Disorders","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CRVO\">CervoMed</a> Publishes Corporate Presentation on Neflamapimod Development for Age-Related Brain Disorders\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CervoMed Inc. highlighted progress for its lead candidate neflamapimod, an oral small-molecule p38α inhibitor being developed for age-related brain disorders. The company outlined plans to initiate a Phase 3 trial in dementia with Lewy bodies in the second half of 2026, and said Phase 2a enrollment is ongoing in non-fluent variant primary progressive aphasia and recovery after ischemic stroke, with data readouts expected in mid-2026 (nfvPPA) and the second half of 2026 (RAS). The presentation also summarized prior DLB study findings, including Phase 2a results showing improvements on CDR-SB and gait measures, and Phase 2b extension-phase analyses in which participants receiving a drug product batch that achieved target plasma concentrations showed improved CDR-SB and ADCS-CGIC outcomes versus an earlier batch. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief on February 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CervoMed Publishes Corporate Presentation on Neflamapimod Development for Age-Related Brain Disorders</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCervoMed Publishes Corporate Presentation on Neflamapimod Development for Age-Related Brain Disorders\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-18 23:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CRVO\">CervoMed</a> Publishes Corporate Presentation on Neflamapimod Development for Age-Related Brain Disorders\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CervoMed Inc. highlighted progress for its lead candidate neflamapimod, an oral small-molecule p38α inhibitor being developed for age-related brain disorders. The company outlined plans to initiate a Phase 3 trial in dementia with Lewy bodies in the second half of 2026, and said Phase 2a enrollment is ongoing in non-fluent variant primary progressive aphasia and recovery after ischemic stroke, with data readouts expected in mid-2026 (nfvPPA) and the second half of 2026 (RAS). The presentation also summarized prior DLB study findings, including Phase 2a results showing improvements on CDR-SB and gait measures, and Phase 2b extension-phase analyses in which participants receiving a drug product batch that achieved target plasma concentrations showed improved CDR-SB and ADCS-CGIC outcomes versus an earlier batch. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief on February 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL8krSFZ:1","article_id":"2612444486","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612444486","pubTimestamp":1771427819,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CervoMed Inc. highlighted progress for its lead candidate neflamapimod, an oral small-molecule p38α inhibitor being developed for age-related brain disorders. The company outlined plans to initiate a Phase 3 trial in dementia with Lewy bodies in the second half of 2026, and said Phase 2a enrollment is ongoing in non-fluent variant primary progressive aphasia and recovery after ischemic stroke, with data readouts expected in mid-2026  and the second half of 2026 . The presentation also summarized prior DLB study findings, including Phase 2a results showing improvements on CDR-SB and gait measures, and Phase 2b extension-phase analyses in which participants receiving a drug product batch that achieved target plasma concentrations showed improved CDR-SB and ADCS-CGIC outcomes versus an earlier batch. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to pro","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CRVO":"CervoMed"},"translate_title":"CervoMed发布关于Neflamapimod开发治疗年龄相关脑部疾病的公司演示文稿","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRVO":0.9},"content_text":"CervoMed Publishes Corporate Presentation on Neflamapimod Development for Age-Related Brain Disorders\n    \n\n        CervoMed Inc. highlighted progress for its lead candidate neflamapimod, an oral small-molecule p38α inhibitor being developed for age-related brain disorders. The company outlined plans to initiate a Phase 3 trial in dementia with Lewy bodies in the second half of 2026, and said Phase 2a enrollment is ongoing in non-fluent variant primary progressive aphasia and recovery after ischemic stroke, with data readouts expected in mid-2026 (nfvPPA) and the second half of 2026 (RAS). The presentation also summarized prior DLB study findings, including Phase 2a results showing improvements on CDR-SB and gait measures, and Phase 2b extension-phase analyses in which participants receiving a drug product batch that achieved target plasma concentrations showed improved CDR-SB and ADCS-CGIC outcomes versus an earlier batch. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief on February 18, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}